New drug combo for advanced lung cancer after TKI failure
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two experimental drugs (ASKC202 and limertinib) against standard chemotherapy for people with advanced non-small cell lung cancer that has a MET gene change and has stopped responding to earlier targeted therapy (EGFR-TKI). It aims to see if the new combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced non-small cell lung cancer that has spread or cannot be removed by surgery
- Your cancer grew while on an EGFR-targeted pill (like erlotinib or osimertinib)
- Your tumor has a MET gene change (amplification or overexpression) confirmed by a central lab
- You have at least one tumor that can be measured on scans
- You are able to get out of bed and care for yourself (ECOG 0 or 1)
- You have not received prior treatment targeting MET, and have not had chemotherapy for advanced lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new Locally Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.